Cargando…
Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer
OBJECTIVES: Ground-glass opacity (GGO) on computed tomography is associated with prognosis in early-stage non-small cell lung cancer (NSCLC) patients. However, the stratification of the prognostic value of GGO is controversial. We aimed to evaluate clinicopathologic characteristics of early-stage NS...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206049/ https://www.ncbi.nlm.nih.gov/pubmed/35715654 http://dx.doi.org/10.1186/s13244-022-01235-2 |
_version_ | 1784729257929342976 |
---|---|
author | Yoon, Dong Woog Kim, Chu Hyun Hwang, Soohyun Choi, Yoon-La Cho, Jong Ho Kim, Hong Kwan Choi, Yong Soo Kim, Jhingook Shim, Young Mog Shin, Sumin Lee, Ho Yun |
author_facet | Yoon, Dong Woog Kim, Chu Hyun Hwang, Soohyun Choi, Yoon-La Cho, Jong Ho Kim, Hong Kwan Choi, Yong Soo Kim, Jhingook Shim, Young Mog Shin, Sumin Lee, Ho Yun |
author_sort | Yoon, Dong Woog |
collection | PubMed |
description | OBJECTIVES: Ground-glass opacity (GGO) on computed tomography is associated with prognosis in early-stage non-small cell lung cancer (NSCLC) patients. However, the stratification of the prognostic value of GGO is controversial. We aimed to evaluate clinicopathologic characteristics of early-stage NSCLC based on the consolidation-to-tumor ratio (CTR), conduct multi-pronged analysis, and stratify prognosis accordingly. METHODS: We retrospectively investigated 944 patients with clinical stage IA NSCLC, who underwent curative-intent lung resection between August 2018 and January 2020. The CTR was measured and used to categorize patients into six groups (1, 0%; 2, 0–25%; 3, 25–50%; 4, 50–75%; 5, 75–100%; and 6, 100%). RESULTS: Pathologic nodal upstaging was found in 1.8% (group 4), 9.0% (group 5), and 17.4% (group 6), respectively. The proportion of patients with a high grade of tumor-infiltrating lymphocytes tended to decrease as the CTR increased. In a subtype analysis of patients with adenocarcinoma, all of the patients with predominant micro-papillary patterns were in the CTR > 50% groups, and most of the patients with predominant solid patterns were in group 6 (47/50, 94%). The multivariate analysis demonstrated that CTR 75–100% (hazard ratio [HR], 3.85; 95% confidence interval [CI], 1.58–9.36) and CTR 100% (HR, 5.58; 95% CI, 2.45–12.72) were independent prognostic factors for DFS, regardless of tumor size. CONCLUSION: We demonstrated that the CTR could provide various noninvasive clinicopathological information. A CTR of more than 75% is the factor associated with a poor prognosis and should be considered when making therapeutic plans for patients with early-stage NSCLC. |
format | Online Article Text |
id | pubmed-9206049 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-92060492022-06-19 Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer Yoon, Dong Woog Kim, Chu Hyun Hwang, Soohyun Choi, Yoon-La Cho, Jong Ho Kim, Hong Kwan Choi, Yong Soo Kim, Jhingook Shim, Young Mog Shin, Sumin Lee, Ho Yun Insights Imaging Original Article OBJECTIVES: Ground-glass opacity (GGO) on computed tomography is associated with prognosis in early-stage non-small cell lung cancer (NSCLC) patients. However, the stratification of the prognostic value of GGO is controversial. We aimed to evaluate clinicopathologic characteristics of early-stage NSCLC based on the consolidation-to-tumor ratio (CTR), conduct multi-pronged analysis, and stratify prognosis accordingly. METHODS: We retrospectively investigated 944 patients with clinical stage IA NSCLC, who underwent curative-intent lung resection between August 2018 and January 2020. The CTR was measured and used to categorize patients into six groups (1, 0%; 2, 0–25%; 3, 25–50%; 4, 50–75%; 5, 75–100%; and 6, 100%). RESULTS: Pathologic nodal upstaging was found in 1.8% (group 4), 9.0% (group 5), and 17.4% (group 6), respectively. The proportion of patients with a high grade of tumor-infiltrating lymphocytes tended to decrease as the CTR increased. In a subtype analysis of patients with adenocarcinoma, all of the patients with predominant micro-papillary patterns were in the CTR > 50% groups, and most of the patients with predominant solid patterns were in group 6 (47/50, 94%). The multivariate analysis demonstrated that CTR 75–100% (hazard ratio [HR], 3.85; 95% confidence interval [CI], 1.58–9.36) and CTR 100% (HR, 5.58; 95% CI, 2.45–12.72) were independent prognostic factors for DFS, regardless of tumor size. CONCLUSION: We demonstrated that the CTR could provide various noninvasive clinicopathological information. A CTR of more than 75% is the factor associated with a poor prognosis and should be considered when making therapeutic plans for patients with early-stage NSCLC. Springer Vienna 2022-06-17 /pmc/articles/PMC9206049/ /pubmed/35715654 http://dx.doi.org/10.1186/s13244-022-01235-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Yoon, Dong Woog Kim, Chu Hyun Hwang, Soohyun Choi, Yoon-La Cho, Jong Ho Kim, Hong Kwan Choi, Yong Soo Kim, Jhingook Shim, Young Mog Shin, Sumin Lee, Ho Yun Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer |
title | Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer |
title_full | Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer |
title_fullStr | Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer |
title_full_unstemmed | Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer |
title_short | Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer |
title_sort | reappraising the clinical usability of consolidation-to-tumor ratio on ct in clinical stage ia lung cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206049/ https://www.ncbi.nlm.nih.gov/pubmed/35715654 http://dx.doi.org/10.1186/s13244-022-01235-2 |
work_keys_str_mv | AT yoondongwoog reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer AT kimchuhyun reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer AT hwangsoohyun reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer AT choiyoonla reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer AT chojongho reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer AT kimhongkwan reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer AT choiyongsoo reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer AT kimjhingook reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer AT shimyoungmog reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer AT shinsumin reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer AT leehoyun reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer |